Danish pharmaceutical company Novo Nordisk has halved the list prices of its obesity drug Wegovy in certain Chinese provinces in anticipation of expected competition from generic versions. This was reported by Yicai, according to Bloomberg News.

In the provinces of Yunnan and Sichuan, prices for the two highest doses have reportedly been reduced to 987.48 and 1 284.36 yuan, equivalent to 1 290 and 1 675 Swedish kronor, respectively.

The company was quoted by Yicai as saying that the price reduction is intended to lower patients' costs and improve adherence to treatment.

Bloomberg has reached out to Novo Nordisk for comment.